Dandekar Atul 4

What Happened
Atul Dandekar, CSBO of Maze Therapeutics, exercised 7,500 stock options (transaction code M) on March 30, 2026 at a strike of $10.42 for a cash cost of $78,150. On the same day he sold a total of 7,500 shares (transaction code S) in open‑market transactions: 6,710 shares at a weighted average price of $29.26 (proceeds ≈ $196,305) and 790 shares at a weighted average price of $30.02 (proceeds ≈ $23,714), totaling about $220,019. The filing also shows a disposition of 7,500 derivative shares at $0.00 (reported separately).

Key Details

• Transaction date: 2026-03-30 (Form 4 filed 2026-04-01 — timely filing).
• Exercise: 7,500 shares acquired at $10.42 each — total cost $78,150. (Code M)
• Sales: 6,710 shares sold at a weighted avg $29.26 (prices ranged $28.86–$29.84) and 790 shares sold at a weighted avg $30.02 (prices ranged $29.87–$30.24). Total sale proceeds ≈ $220,019. (Code S)
• Reported derivative disposition: 7,500 shares at $0.00 (listed separately).
• Notable footnotes: transaction executed under a Rule 10b5‑1 trading plan adopted Sept 29, 2025 (F1); option award was fully vested as of March 17, 2025 (F4). F2/F3 note the sales prices are weighted averages across multiple trades.
• Shares owned after the transactions: not specified in the provided excerpt of the filing.

Context

• Codes: M = exercise/conversion of derivative (option exercise); S = open‑market sale.
• The sequence—exercise and near‑simultaneous sales reported the same day and the presence of a 10b5‑1 plan—indicates these were planned transactions rather than ad‑hoc purchases; this pattern is commonly used to cover the exercise cost, tax withholding, or to monetize vested awards.
• Sales are routine insider activity and do not by themselves indicate company prospects; purchases generally carry more weight for signaling.